Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

Recruiting

Phase 1

Abemaciclib with 5-FluorouracilTesting the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT06654037

Conditions

Metastatic Microsatellite Stable Colorectal Carcinoma

Refractory Microsatellite Stable Colorectal Carcinoma

Stage IV Colorectal Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Abemaciclib

Biopsy Procedure

Biospecimen Collection

Fluorouracil

Radiologic Imaging Procedure

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-27. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-07-09.